FDA Approves Oral Drugs for Ovarian Cancer Maintenance Therapy
The U.S. Food and Drug Administration (FDA) has approved several oral drugs, known as PARP inhibitors, for treating ovarian cancer. These drugs, taken once or twice daily with or without food, have shown promising results in extending progression-free survival. The FDA approved Olaparib, Niraparib, and Rucaparib between 2014 and 2018, along with the angiogenesis inhibitor Bevacizumab.
PARP inhibitors work by blocking an enzyme that repairs DNA in cancer cells, leading to their death. Meanwhile, angiogenesis inhibitors like Bevacizumab prevent cancer cells from forming new blood vessels, starving them of oxygen and nutrients. These drugs are often used in maintenance therapy, a treatment approach aimed at delaying cancer recurrence after initial chemotherapy. Maintenance therapy with PARP inhibitors and angiogenesis inhibitors has been shown to extend the time between initial treatment and cancer recurrence. Common side effects of these maintenance therapies include elevated blood pressure, fatigue, nausea, and changes in blood counts.
PARP inhibitors and angiogenesis inhibitors have become crucial tools in the fight against ovarian cancer. Their approval by the FDA has expanded treatment options, offering hope for extended progression-free survival. As with any treatment, it's essential to discuss potential benefits and side effects with healthcare providers.
Read also:
- Rosselkhozbank's Yakutsk Branch Expands 'Farmer School' to Train SVO Veterans in Agribusiness
- Emerging Fashions in Marijuana Storage: TVLPK's Attractive Gear for Cannabis Carrying
- The Distinction Between Sexual Identity and Gender Identity
- Symptoms, Prevention Strategies, and Management Methods for Measles
